Treatment of a murine model of systemic candidiasis with liposomal amphotericin B bearing antibody to Candida albicans.
Survival of mice infected with an intravenous injection of Candida albicans was observed in a short-term (21-day) survival study. Concentration of C. albicans in the kidneys, liver, and spleen was determined at various times. The effects of treatment with the commercial formulation of amphotericin B (fAMB), liposomal amphotericin B (LAMB), and liposomal amphotericin B bearing external antibody specific for C. albicans (LAMB-Ab) were compared. In single intravenous treatment dosages of 0.6 mg of amphotericin B/kg, the liposomal forms of the drug (LAMB and LAMB-Ab) enhanced the percentage survival and mean survival time of mice in comparison with those treated with the unencapsulated antifungal compound, fAMB (p less than 0.03 and p less than 0.001, respectively). LAMB-Ab, at this dosage, produced an increase in the survival (p less than 0.007) of mice over that produced by LAMB. LAMB-Ab treatment caused a greater than 3-fold increase over fAMB. The percentage of LAMB-Ab-treated mice which survived for 21 days was almost double that of the LAMB-treated mice. The increase in survival following this treatment did not, however, lead to the eradication of C. albicans in all mice which survived to the end of the experiment.